Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Redhill Biopharma Ltd. - American Depositary Shares (NQ:RDHL)

1.630 -0.080 (-4.68%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Redhill Biopharma Ltd. - American Depositary Shares

RedHill Biopharma Ltd. (NASDAQ: RDHL) is One of Wednesday Morning’s Most Active Stocks
Via Investor Brand Network
RedHill Biopharma Ltd Announces RDHL Opaganib Selected by NIH RNCP For Development
Via ACCESSWIRE
RedHill Biopharma Ltd Announces RedHill's RHB-102 Positive MHRA Meeting & MAA Plan
Via ACCESSWIRE
Aegis Capital Corp. Acted as Sole Bookrunner on an $8 Million Underwritten Public Offering for RedHill Biopharma Ltd. (NASDAQ:RDHL)
Via ACCESSWIRE
RedHill Biopharma Ltd Announces Potent Omicron Inhibition with RedHill's Opaganib
Oral opaganib's reported potent in vitro activity against Omicron adds to previously observed inhibition of Delta and other SARS-CoV-2 variants of concern that cause COVID-19; Testing conducted by The... 
From RedHill Biopharma Ltd
Via AccessWire
RedHill Announces Additional Insider Buying
RALEIGH, NC and TEL-AVIV, ISRAEL / ACCESSWIRE / December 15, 2021 / RedHill Biopharma Ltd. (NASDAQ:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that... 
From RedHill Biopharma Ltd
Via AccessWire
RedHill Biopharma Ltd Announces Concerning Clarithromycin Rx Rates for H. pylori
RedHill Biopharma: Concerning Rates of Clarithromycin Prescribing for H. pylori, Despite Increasing Antibiotic Resistance, Uncovered in New Digestive Diseases & Sciences Publication Despite increasing... 
From RedHill Biopharma Ltd
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Anxious World Waits As Covid Vaccine Makers Address Omicron Variant
Palm Beach, FL – December 7, 2021 – FinancialNewsMedia.com News Commentary There are many unknowns surrounding the new omicron Covid variant; there are early signs it’s more transmissible, but it’s not... 
Via FinancialNewsMedia
RedHill Biopharma Ltd - Opaganib MoA Not Impacted by Omicron Mutations
Unique Mode of Action Opaganib works by targeting the human host cell rather than the virus itself and is therefore not expected to be impacted by spike protein mutations, providing a strong rationale... 
From RedHill Biopharma Ltd
Via AccessWire
Topics Intellectual Property Regulatory Compliance
RedHill Biopharma Ltd Announces Talicia: Consistent Efficacy Irrespective of BMI
RedHill Biopharma Data Published in GastroHep Shows Consistent Efficacy of Talicia Irrespective of Patient BMI High Body Mass Index and obesity are known risk factors for H. Pylori eradication... 
From RedHill Biopharma Ltd
Via AccessWire
Topics Intellectual Property Regulatory Compliance
RedHill’s Movantik Added To Medicare Formulary
RedHill Biopharma's Movantik® Added as Preferred and Unrestricted Brand To Major National Medicare Formulary Serving Millions of Americans Movantik® approved for inclusion as preferred and unrestricted... 
From RedHill Biopharma Ltd
Via AccessWire
Topics Intellectual Property Regulatory Compliance
RedHill Reports 3Q/2021 Financial Results
RedHill Biopharma Reports Operational Highlights and Third Quarter 2021 Financial Results RedHill Accelerates its Two Advanced COVID-19 Pill Clinical Programs in Light of their Potential Against... 
From RedHill Biopharma Ltd
Via AccessWire
Topics Intellectual Property Regulatory Compliance
RedHill Biopharma Ltd Announces RedHill: LPI in Part A of RHB-107 P2/3 COVID Study
RedHill Biopharma Announces Last Patient Randomized in Part A of Ongoing Phase 2/3 COVID-19 Study of Once-Daily Oral RHB-107 in Non-Hospitalized Patients Recruitment completed for Part A of the Phase... 
From RedHill Biopharma Ltd
Via AccessWire
Topics Intellectual Property Regulatory Compliance
RedHill Biopharma and South Korea's Kukbo Co. Announce a Strategic Investment of Up To $10 Million in RedHill
RedHill received the first tranche of $5 million in a private placement of restricted stock priced at $6.04 per ADS, representing a 20% premium based on the 30 trading days' volume weighted average... 
From RedHill Biopharma Ltd
Via AccessWire
Topics Intellectual Property Regulatory Compliance
RedHill Biopharma Presents New Talicia(R) and Movantik(R) Data Analyses at ACG 2021
Two new analyses evaluate pharmacological and clinical advantages of Talicia® as first-line H. pylori therapy over clarithromycin-based regimens - Two new analyses of Movantik® data evaluate efficacy... 
From RedHill Biopharma Ltd
Via AccessWire
Topics Intellectual Property Regulatory Compliance
RedHill Biopharma Announces Insider Buying
TEL-AVIV, ISRAEL and RALEIGH, NC / ACCESSWIRE / October 18, 2021 / RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that... 
From RedHill Biopharma Ltd
Via AccessWire
Topics Intellectual Property Regulatory Compliance
RedHill Biopharma Ltd Announces New U.S. Patent for RedHill's Talicia for H.pylori
RedHill Biopharma Announces New U.S. Patent Covering Talicia for H. pylori Infection Through 2034 The patent is directed to the Talicia® formulation and pharmaceutical kits for use in the treatment of... 
From RedHill Biopharma Ltd
Via AccessWire
Topics Intellectual Property Regulatory Compliance
RedHill Biopharma Ltd Announces Talicia(R) added to Medi-Cal CDL
RedHill Biopharma's Talicia® added to Medi-Cal Contract Drug List with No Prior Authorization Requirements Addition of Talicia® by Medi-Cal Fee-For-Service (FFS) Contract Drug List (CDL) with no prior... 
From RedHill Biopharma Ltd
Via AccessWire
Topics Intellectual Property Regulatory Compliance
RedHill Biopharma Reports Further Analysis of Phase 2/3 Data Including a 62% Reduction in Mortality with Oral Opaganib in Moderately Severe COVID-19 Patients
62% statistically significant reduction in mortality shown for moderately severe COVID-19 patients group treated with opaganib vs. the placebo-controlled arm (7 deaths in the 117-patient opaganib arm... 
From RedHill Biopharma Ltd
Via AccessWire
Topics Death Intellectual Property Regulatory Compliance
RHB-107 P2/3 COVID-19 Study South Africa Approval
RedHill Biopharma Accelerates Ongoing U.S. Phase 2/3 COVID-19 Study of Once-Daily Oral RHB-107 in Non-Hospitalized Patients with South African Approval The South African Health Products Regulatory... 
From RedHill Biopharma Ltd
Via AccessWire
Topics Intellectual Property Regulatory Compliance
RedHill Biopharma's Opaganib Demonstrates Significant Decrease of Kidney Fibrosis
COVID-19 and long COVID patients are at increased risk of developing kidney damage - Opaganib significantly decreased kidney fibrosis in a preclinical in vivo model - Renal fibrosis is a progressive... 
From RedHill Biopharma Ltd
Via AccessWire
Topics Intellectual Property Regulatory Compliance
RedHill Biopharma Ltd Announces New Movantik Analyses at PAINWeek
RedHill Biopharma Presents Three New Analyses of Movantik Data at PAINWeek 2021 Two new analyses of Movantik® (naloxegol) data evaluated the safety and efficacy of Movantik in a subgroup of patients... 
From RedHill Biopharma Ltd
Via AccessWire
Topics Intellectual Property Regulatory Compliance
RedHill to Present at HCW & Cantor Conferences
RedHill Biopharma to Present at H.C. Wainwright Annual Global Investment and Cantor Global Healthcare Conferences TEL AVIV, ISRAEL and RALEIGH, NC / ACCESSWIRE / September 2, 2021 / RedHill Biopharma... 
From RedHill Biopharma Ltd
Via AccessWire
Topics Intellectual Property Regulatory Compliance
RedHill Reports Second Quarter 2021 Results
- Achieved record quarterly revenues of $21.5 million for Q2/2021, 4.5% increase from Q1/2021 despite challenging market conditions; Cash balance[1] of approximately $71.5 million as of June 30, 2021 -... 
From RedHill Biopharma Ltd
Via AccessWire
Topics Intellectual Property Regulatory Compliance Supply Chain
RedHill Biopharma Ltd Announces RedHill's Opaganib Strong Delta Variant Inhibition
RedHill Biopharma's Opaganib Demonstrates Strong Inhibition of COVID-19 Delta Variant Opaganib demonstrated strong inhibition of COVID-19 Delta variant in a human bronchial epithelial cells model,... 
From RedHill Biopharma Ltd
Via AccessWire
Topics Intellectual Property Regulatory Compliance
RedHill Announces Two New U.S. Patents
RedHill Biopharma Announces Two New U.S. Patents Covering Opaganib for Ebola Virus and RHB-104 for Crohn's U.S. patents for opaganib combination for the treatment of Ebola virus disease provides patent... 
From RedHill Biopharma Ltd
Via AccessWire
Topics Intellectual Property Regulatory Compliance
RedHill Extends Talicia Commercial Coverage
RedHill Biopharma Significantly Extends Unrestricted Commercial Coverage for Talicia® with OptumRx Addition of Talicia® by OptumRx significantly extends Commercial patient access to Talicia® through... 
From RedHill Biopharma Ltd
Via AccessWire
Topics Intellectual Property Regulatory Compliance
RedHill Biopharma Ltd Announces RedHill Biopharma Announces Last Patient Out
RedHill Biopharma Announces Last Patient Out for Phase 2/3 COVID-19 Study of Oral Opaganib Patient follow-up completed for the 475-patient global Phase 2/3 study of oral opaganib for severe COVID-19... 
From RedHill Biopharma Ltd
Via AccessWire
Topics Intellectual Property Regulatory Compliance
35 of the Best Ideas Companies to Present at the Summer Solstice - Best Ideas from the Buy-Side Virtual Investor Conference on June 1-4, 2021
RALEIGH, NC / ACCESSWIRE / May 27, 2021 / The Summer Solstice - Best Ideas from the Buy-Side will take place on June 1-4, 2021, where 35 SmallCap, MicroCap and NanoCap public companies will be... 
From MicroCap Rodeo
Via AccessWire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.